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Abstract
Fractional flow reserve (FFR) is an evidence-based diagnostic tool of physiological significance of 
coronary artery stenosis in patients with stable coronary artery disease (CAD). Due to microvascular 
dysfunction in acute coronary syndrome (ACS), information obtained from FFR assessment could be 
less reliable and, thus, its clinical role remains controversial. Indeed, results of currently published 
studies are essentially discrepant. Only a few randomized clinical trials have been performed showing 
the efficacy of FFR-guided percutaneous coronary intervention in ACS. Consequently, its role in acute 
scenarios remains substantially understudied. Herein, is presented the current state of knowledge re-
garding FFR use in ACS setting. (Cardiol J 2017; 24, 4: 426–435)
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Introduction
Fractional flow reserve (FFR)-guided percuta-
neous coronary intervention (PCI) [1, 2] improves 
long-term outcome and reduces cost in coronary 
artery disease (CAD) settings as compared with 
angiographic-guided PCI [3, 4]. The value of FFR 
is an integrated way associated with an ability to 
produce maximal hyperemia to achieve a linear 
relation between pressure and flow [5, 6]. Maximal 
hyperemia in FFR assessment is a simulation of the 
working heart in physical effort conditions under 
the influence of potent vasodilators [5, 7]. Due to 
microcirculatory dysfunction, hyperemia in the 
acute course of acute coronary syndrome (ACS) 
may not be optimal [8, 9].
Results of currently published studies inves-
tigating the use of FFR assessment in ACS are 
discrepant. Some suggest that measurement of 
FFR is reliable in ACS, mainly in patients with non-
ST-elevation myocardial infarction (NSTEMI) [10, 
11]; others show differences in FFR values in acute 
course when compared with FFR assessment after 
a few weeks or months [12]. Only a few randomized 
clinical trials (RCT) have been performed showing 
the efficacy of FFR-guided PCI in ACS. Thus, its 
role in acute scenarios remains understudied [2].
Clinical aspects of coronary physiology 
Fractional flow reserve is defined as the ratio 
of pressure measured distally to the stenosis (Pd) 
to the pressure in the aorta (Pa) under conditions 
of maximal hyperemia [5, 7, 13]. A body of evidence 
demonstrates that FFR of < 0.80 remains the gold 
standard for the necessity of invasive treatment 
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[14, 15]. However, FFR is only one element when 
determining whether or not to treat a patient 
invasively.
Additional parameters that influence the FFR 
value include the wedge pressure in the coronary 
arteries (Pw) derived from collateral circulation 
and venous vessels of the heart as well as venous 
pressure (Pv), arising from pressure in the right 
atrium [13]. Myocardial FFR is calculated using the 
venous pressure (Pv), by the formula FFRmyo = 
[Pd – Pv]/[Pa – Pv]; in fact, Pv values are negligible, 
and in the majority of cases, do not impact the final 
FFR result [13]. These parameters have not been 
taken into account in large RCTs with regard to the 
usefulness of FFR in coronary revascularization 
(Fig. 1) [3, 4].
Pharmacological hyperemia
The most widely utilized, and thus, most stud-
ied medication used for the induction of hyperemia 
while assessing FFR is adenosine [16]. It is used 
primarily intravenously (i.v.), but intracoronary 
(i.c.) administration of the drug is also permitted. 
No major differences have been demonstrated in 
the FFR measurement when comparing the differ-
ent routes of administration of adenosine [17, 18]. 
As i.v. adenosine can be used over a longer period; 
it provides more time in obtaining a reliable mea-
surement. It also has a lower risk of side effects, 
i.e. arrhythmias [19–21]. Use of adenosine in the 
assessment of FFR, when given i.v., is done most 
often as a continuous infusion in the dose 140 µg/ 
/kg/min, though larger doses are acceptable [16]. 
When given as an i.c. dose, a bolus is used in the 
range of 100 to even 500 µg. Optimal effects are 
usually achieved at a dose of 200 µg to the left 
coronary artery, and about 100–150 µg to the right 
coronary artery [22]. The bolus may be repeated, 
simultaneously increasing the dosage of the drug 
[16]. An essential fact to consider while adminis-
tering adenosine is the potential usage of caffeine 
by the patient, which is an antagonist of adenosine 
Figure 1. Systemic and coronary vascular beds that influence fractional flow reserve (FFR) [7]; Ao — aortic pressure; 
Pa — arterial pressure proximal to stenosis; Pd — coronary pressure distal to epicardial stenosis; Pv — venous 
pressure; Qc — collateral blood flow; Rc — collateral resistance; Rs — epicardial coronary stenosis; IMR — index of 
microvascular resistance; CFR — coronary flow reserve.
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positron emission tomography [8], angiography 
(corrected Thrombolysis in Myocardial Infarction 
[TIMI] frame count) [33] and Doppler [34] also 
suggest a widened microvascular dysfunction 
both in the area of the culprit and non-culprit 
vessels in patients with STEMI. These processes 
fundamentally indicate extensive ischemia in 
adjoining areas of cardiac muscle, vasoconstric-
tion caused by local neurohormonal reactions 
[35] as well as an increase in the end-diastolic 
pressure in the left ventricle (LVEDP) [34]. 
Further studies show that even isolated suben-
docardial ischemia (which occurs in patients with 
NSTEMI) can cause an important microvascular 
dysfunction of the cardiac muscle as a whole 
[8, 36–40].
The second issue often debated is defining 
the length of time necessary for microcirculation, 
if affected in its’ entirety, to regain its’ function. 
The amount of time required for microcirculation 
of the cardiac muscle, if it was impaired, to regain 
functioning after MI is shown in the literature to 
last from 7 days to 3 months [8, 41] and even up 
to 6 months [12].
Additional aspects of FFR measurement 
in patients presenting with ACS 
Fractional flow reserve measurement, wheth-
er or not it is justified in MI, does have some dis-
advantages. Above all, it prolongs the procedure, 
which is related to the need for additional amounts 
of contrast and radiation. Patients with stable 
CAD, when properly informed and prepared for 
catheterization, physically via hydration, as well 
as psychologically, they understand the need to 
prolong the examination for the FFR measurement 
and are prepared for a longer stay in the cath lab. In 
patients with ACS, who are often suddenly admit-
ted to the hospital, this fact alone is already a larger 
stress, and any prolonged testing is associated 
with additional negative emotions. Additionally, 
patients are often dehydrated with an unknown 
status regarding potential kidney dysfunction. The 
disadvantages of FFR measurement, however, 
could be outweighed by an advantage, if performing 
the measurement aids in determining the planned 
treatment of patients with ACS. 
The current standard in functional assess-
ment of the area of non-culprit stenosis is nonin-
vasive testing that is performed during the first 
few days or weeks after MI. This testing often 
prolongs hospitalization, can be expensive, and 
the interpretation of them quickly after an acute 
receptors and may affect the FFR measurement. 
Matsuomo et al. [23] proved that patients who 
ingested caffeine within 24 h prior to FFR measure-
ment had underestimated values of FFR despite 
requiring larger doses of adenosine, in comparison 
with those patients who avoided caffeine > 24 h. 
The FFR values for comparison of the accuracy of 
FFR measurement were performed using papaver-
ine as the drug to induce hyperemia in this study. 
Importantly, bronchial asthma is an absolute 
contraindication to the use of adenosine as it may 
cause bronchospasm, which rarely occurs even in 
patients without known pulmonary disease [24]. 
Other substances that can be used to induce 
hyperemia during the measurement of FFR include 
i.v. regadenoson (agonist of adenosine receptor 
A2A) [25], i.c. sodium nitroprusside [26], nicorandil 
[27], nitrates [28] and papaverine [17, 29]. It is im-
portant to note that these substances are much less 
frequently used and thus, do not often appear in the 
protocols for large RCTs. However, interestingly, 
when used to produce hyperemia, they do provide 
a proper and comparative effect [18].
Microvascular resistance is not  
minimized in recently infarcted  
myocardium
As previously mentioned, most of the data to 
date has been derived from stable CAD subsets. 
Of note, FFR measurement in ACS may be less 
reliable due to the limited ability of microcircula-
tion to react to pharmacological vasodilatation, 
which can lead to false negative results, and 
underestimate the degree of stenosis, especially 
in the culprit vessel during STEMI [8, 30]. How-
ever, the FFR-measurement in ACS may prove 
to be particularly useful in the case of patients 
with multi-vessel (MVD) CAD. Both in STEMI 
and NSTEMI, the key point of strategy is to 
identify the culprit lesion, as revascularization 
can be postponed in non-culprit vessels. In fact, 
the one-step full revascularization strategy in 
non-compromised ACS patients still remains 
a matter of debate. The most often discussed 
issue regarding the reliability of FFR in ACS is 
the area of coronary microvascular dysfunction 
during an MI. Indeed, the microvascular dysfunc-
tion most often affects the area of cardiac muscle 
supplied by the culprit vessel. However, it can be 
present throughout the entire myocardium [31, 
32]. Experiments on animals show that necrosis 
and metabolic disorders also affect non-culprit 
zones [31, 32]. Studies performed with the use of 
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event is ambiguous with regard to whether the 
patient will require subsequent invasive test-
ing [42]. A body of evidence has described FFR 
measurement as an interesting and effective di-
agnostic alternative in patients presenting with 
ACS and MVD. The main benefits of measuring 
FFR is that it is reproducible and highly specific. 
Additionally, this measurement, when performed 
in experienced centers, can be completed within 
a few minutes [43].
Landmark Studies of FFR-guided  
strategy in ACS subsets (Table 1)
FFR-guided vs. angiographic-guided  
management in ACS
The FAMOUS-NSTEMI study compared an-
giographic assessment with FFR measurements 
with regards to determining further treatment 
in non-compromised patients with NSTEMI 
[10, 11]. Patients were randomly assigned into 
one of three groups: coronary artery bypass 
graft (CABG), PCI or conservative treatment. 
Interestingly, the use of FFR lowered the need 
for revascularization. The results of FFR meas-
urement in the FFR-guided group changed the 
method of treatment in 38 patients (Fig. 2). 
There were essentially no differences between 
groups regarding major adverse cardiac events 
(MACE). No cases of adverse drug reactions 
related to the use of adenosine were recorded. 
The FAMOUS-NSTEMI [10, 11] trial was cre-
ated on the basis of the FAME trial [3], with the 
main differences seen in the type of patients who 
took part in the study (NSTEMI vs. CAD) as well 
as the degree of stenosis which was assessed 
(lesions ≥ 30% vs. ≥ 50%) [10, 11]. A sub-study 
of FAMOUS-NSTEMI [10, 11] compared FFR 
results with perfusion-magnetic resonance 
imaging (MRI) studies, and confirmed the di-
agnostic significance of FFR in stable patients 
with NSTEMI.  
The COMPARE-ACUTE [44] trial compared 
FFR-guided complete revascularization (n = 295) 
with culprit artery only revascularization (infarct 
related artery [IRA], n = 590) among patients with 
primary PCI presented with STEMI. Complete 
revascularization was performed during primary 
PCI or as a second procedure no later than 72 h 
from admission to the hospital. Significant stenosis 
Figure 2. Impact of fractional flow reserve (FFR) disclosure on treatment decisions based on standard angiography-
-alone in the FAMOUS-NSTEMI clinical trial [11]. CABG — coronary artery bypass graft; OMT — optimal medical 
therapy; PCI — percutaneous coronary intervention.
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of the non-culprit vessel was considered ≥ 50% 
stenosis. It turned out that in STEMI patients, 
FFR-guided compete revascularization was supe-
rior to the IRA group in MACE points at 12 months 
observation (7.8% vs. 20.5%, p < 0.001). It is worth 
emphasizing that there were no differences in MI 
and mortality. Most importantly, that patients in 
the IRA group had more re-PCIs when compared 
Table 1. Fractional flow reserve in acute coronary syndrome studies. 
Study Year Patients (n) Aim Conclusion
Samady H, 
et al.  
JACC  
[48]
2006 48 
STEMI 
NSTEMI
To assess if FFR of IRA early 
after MI can be useful in  
identifying ischemia on  
noninvasive imaging 
FFR of the IRA identifies reversibility 
on noninvasive imaging early after MI
Ntalianis A, 
et al.  
JACC  
[46]
2010 101 
STEMI 
NSTEMI
To examine hemodynamic  
severity of the non-culprit 
coronary artery stenoses in  
the acute phase of MI
The severity of non-culprit coronary 
artery stenoses can be reliably  
asseessed by FFR
Cuculi F,  
et al.  
JACC  
[12]
2014 82 
STEMI
To evaluate of CFR, IMR and 
FFR in patients undergoing  
primary PCI in STEMI
Coronary microcirculation begins  
to recover within 24 h and recovery 
progresses further for 6 months after MI. 
FFR significantly reduces from baseline 
to 6 months. The presence  
of MVO indicates a highly  
microvascular dysfunction
Engstrøm T, 
et al.  
Lancet  
[45]
2015 627 
STEMI
To compare FFR-guided com-
plete revascularization with IRA 
among patients undergoing 
primary PCI for STEMI
No significant difference was found 
between the two groups for all-cause 
mortality and non-fatal reinfarction 
at a median of 27 months follow-up, 
patients in the FFR-guided revasculari-
zation group had significantly fewer 
repeat revascularizations
Layland J, 
et al.  
Eur Heart J 
[11]
2015 350 
NSTEMI
To assess outcomes of 
NSTEMI patients assigned to 
FFR-guided management or 
angiographic-guided  
standard care
Angiographic-guided management 
was associated with higher rates of 
coronary revascularization when  
compared with FFR-guided
Layland J,  
et al. Circ 
Cariovasc 
Interv  
[47]
2015 106 
NSTEMI
To assess the diagnostic  
accurancy of FFR compared 
with 3.0-T stress CMR perfusion 
of NSTEMI patients 
FFR in patients with recent NSTEMI 
showed high concordance with  
myocardial perfusion in matched  
territories as revealed by 3.0-T stress 
perfusion CMR
Hakeem A, 
et al.  
JACC  
[50]
2016 206 
STEMI 
NSTEMI
To investigate the clinical and 
prognostic utility of FFR in ACS 
patients with PCI deferred on 
the basis of nonischemic FFR
Deferring PCI on the basis of noni- 
schemic FFR in patients with ACS is 
associated with significantly worse 
outcomes than in stable CAD. Caution  
is warranted in using FFR values derived  
from patients with stable CAD for clini-
cal decision making in ACS patients
Ahmed N, 
et al.  
Int J Cardiol  
[54]
2016 648 
STEMI 
NSTEMI
To assess the safety of guide-
wire-based measurement of 
coronary physiology using i.v. 
adenosine in patients with ACS
Guidewire-based measurement of  
FFR and IMR using i.v. adenosine  
was safe in patients with ACS
Smits PC, 
et al.  
N Engl J Med 
[44]
2017 885 
STEMI
To evaluate FFR-guided  
complete revascularization 
compared with IRA among  
patients undergoing  
primary PCI for STEMI
FFR-guided complete revascularization 
during the index procedure  
was superior to IRA
ACS — acute coronary syndrome; CAD —  coronary artery disease; CFR — coronary flow reserve; CMR — cardiovascular magnetic reso-
nance imaging; FFR — fractional flow reserve; i.v. — intravenously; IMR — microcirculatory resistance; IRA — infarct related artery; MI — 
myocardial infarction; MVO — microvascular obstruction; NSTEMI — non-ST-elevation myocardial infarction; PCI — percutaneous coronary 
intervention; STEMI — ST-elevation myocardial infarction
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with the FFR-guided complete revascularization 
group (17.5% vs. 6.1%, p < 0.001). As in most of 
cases, complete revascularization was performed 
during the primary procedure, thus there were less 
MACEs in the complete FFR-guided revasculariza-
tion. Similarly, no significant difference in MACE 
was recorded in the DANAMI-3-PRIMULTI trial 
[45] after a 27-month follow-up, where STEMI 
patients (n = 627) were randomly assigned (1:1) to 
IRA group and FFR-guided complete revasculariza-
tion group. Again, there was a significantly lower 
rate of further revascularization in the FFR-guided 
complete revascularization group. 
Reliability of FFR assessment in ACS
Ntalianis et al. [46] were the first to assess 
the reliability of FFR measurement in patients 
with ACS. Non-culprit stenosis (n = 112) in the 
range of %DS (diameter stenosis) 30–90%, were 
evaluated, with FFR measurements taken imme-
diately after PCI of the culprit lesion. The FFR 
measurement was obtained and compared at 
35 ± 4 days. Additionally, left ventricular ejection 
fraction, quantitative coronary angiography, flow 
according to TIMI scale and the index of micro-
circulatory resistance (IMR) were assessed in 
fourteen patients (n = 14), during both the acute 
phase and follow-up. The FFR measurements 
did not significantly differ between the acute 
phase and follow-up examinations (0.77 ± 0.13 
vs. 0.77 ± 0.13, p = NS). In 2 patients, the FFR 
value was > 0.80 during the time of MI and was 
< 0.75 in follow-up. In the remaining examined 
parameters, no statistically significant differences 
were noted. The key conclusion of this study 
is that the measurement of FFR in non-culprit 
stenoses of patients with MI, can be performed 
in a reliable manner during the acute phase of 
the disease and allows for planning of a more 
appropriate strategy of individualized treatment 
for each patient.
Notably, the study did have a few limitations 
which may have affected the results and derived 
conclusions. The main dilemma is the length of 
the observational period and timing of the con-
trol angiography with FFR measurement. In the 
initial study parameters, this period was set for 
3 months, but was at most 35 ± 4 days. Accordingly, 
the measurements conducted theoretically in the 
stable phase of disease may have been performed 
during the period when microcirculation was still 
dysfunctional, thus, inducing hyperemia was still 
not possible. This could lead to FFR measurements 
being exaggerated, and correlating closer with the 
results obtained in the acute phase of the disease. 
The second limitation of the study was the dos-
age of adenosine. In the majority of patients, the 
drug was administered i.c. (n = 87) in a dose of 
50 µg [22]. This dose may not have been enough 
to induce hyperemia especially during the follow-
up period when theoretically, the microcirculation 
could already be functional. Using such a small dose 
could cause the results obtained to be essentially 
unreliable.
FFR assessment vs. noninvasive imaging  
in ACS subset 
Layland et al. [47], in the substudy of FA-
MOUS-NSTEMI, compared FFR measurements 
in patients with NSTEMI to results obtained via 
3-T cardiovascular magnetic resonance imaging 
(CMR) (n = 106). Measurements of FFR were 
performed in all lesions of ≥ 30%. In cases where 
PCI was performed, the FFR measurement was 
repeated. Sensitivity, specificity, positive predic-
tive value and negative predictive value for FFR 
≤ 0.80 amounted to 91.4%, 92.2%, 76%, 97%, 
respectively. In patients who had CMR performed 
prior to coronary angiography (n = 21), the posi-
tive and negative predictive value for FFR ≤ 0.80 
was 92% and 93%, respectively. On the basis of 
these results, an optimal cut-off point for FFR 
measurement was determined, representing an 
ischemia in CMR at the level ≤ 0.805. A similar 
study was conducted by Samady et al. [48], of 
48 hemodynamically stable patients with recent MI, 
comparing the FFR measurement in the culprit 
lesion with results obtained from single photon 
emission computed tomography (SPECT) as well 
as those from echocardiography with the use of 
contrast. The average time from angiography to 
noninvasive examination amounted to 3.7 days, 
with 73% of patients diagnosed with STEMI. It 
was concluded that a result of FFR ≤ 0.75 showed 
91% sensitivity, 93% specificity, as well as a diag-
nostic accuracy at the level of 92% for identifying 
reversible ischemia. Interestingly, the optimal 
cut-off for FFR measurement to accurately de-
termine ischemia was ≤ 0.78.
Microvascular function and FFR in ACS 
Cuculi et al. [12] aimed to grade the dynamic 
changes in coronary flow reserve (CFR), the index 
of IMR, and the FFR in patients who underwent 
primary PCI in STEMI (n = 82). Assessment of 
FFR was performed only within the culprit lesion, 
after the previous PCI. A second invasive measure-
ment of coronary physiology was conducted the 
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first day after invasive treatment of MI (n = 61), 
or 6 months later (n = 46). 
Contrast-enhanced MRI was performed 
during the first day of treatment (n = 45) or 
after 6 months (n = 41). Patients were divided 
into two groups, those with and those without 
microvascular obstruction (MVO) of cardiac 
muscle confirmed via CMR. MVO was recog-
nized in 21 (47%) patients. FFR measurements 
were significantly lower after 6 months in com-
parison to FFR measurements obtained during 
the initial PCI (p = 0.008). This phenomenon 
was seen mainly in those with confirmed MVO 
(p = 0.006). The MVO patient group was found 
to have a lower CFR (p < 0.05) and a higher IMR 
(p = 0.07) in their initial measurements (first 
PCI and first day) in comparison to the group of 
patients without MVO. However, in the results 
obtained after 6 months, there were no differ-
ences between the two groups with regard to 
CFR and IMR. It appears that in some patients 
with STEMI, a temporary dysfunction of cardiac 
muscle vasculature does occur, and the process 
of returning this muscle to a state of complete 
recovery can last up to 6 months. The presence 
of MVO causes a significant dysfunction related 
to a limited response to adenosine. Accordingly, 
FFR measurements obtained during ACS may 
underestimate the degree of stenosis in about 
half of STEMI patients.
Authors of the above-presented study claim 
that the process of healing the damaged micro-
circulation can last up to 6 months post infarc-
tion. However, it is likely that the CFR, IMR 
and FFR results are similar much earlier, for 
instance, within 3 months [8, 49]. So far, this 
issue has no exact answer and thus, further 
studies to identify the most optimal period 
for the restoration of microcirculation are still 
warranted.
Do we need other cut-off point for  
FFR assessment in ACS?
One of the latest publications regarding FFR 
assessment in ACS is the work by Hakeem et al. 
[50] where patients with NSTE-ACS (n = 206, 
262 intermediate stenoses) were compared to 
patients with stable CAD (n = 370) with border 
stenoses in coronary arteries (n = 528), who 
were disqualified from PCI after obtaining an 
FFR > 0.75. They compared the frequency of MI 
and the need for target vessel revascularization 
(TVR) over a 3.4 year period of observation. It 
became apparent that the rate of MI and TVR 
was higher in the NSTE-ACS group (25% vs. 
12%; p < 0.0001), as seen in the literature [51, 
52]. The optimal cut-off point for significant 
stenosis in patients with CAD was determined 
to be an FFR measurement of ≤ 0.80, while in 
patients with NSTE-ACS, a measurement of 
≤ 0.84 was noted. One must take into account that 
the results of the second group may be falsely 
negative due to microvascular dysfunction. As 
such, one of the main conclusions of the study is 
the recommendation that patients with NSTE-
-ACS, FFR results between 0.80 and 0.85 fall 
into a gray zone and should be confirmed before 
planning further treatment strategy. Given this 
study’s conclusions, one must consider whether 
FFR assessment in patients with ACS requires 
a different cut-off point than that of patients 
with CAD. 
It is important to touch upon some of the 
limitations of this study, starting with the fact that 
the position of the FFR wire during measurement 
was never mentioned [53]. Secondly, in at least half 
of the patients, adenosine was given ic. in a dose 
of only 130 µg, and in some, even at 60 µg, which 
could lead to suboptimal hyperemia. The third 
limitation of the study is that only patients with 
NSTE-ACS and border angiographic lesions were 
included. Thus, some amount of patients enrolled 
into the study might have elevated troponin levels 
due to other reasons and not essentially myocardial 
ischemia.
Safety of FFR measurement in ACS 
Problems during FFR assessment are often 
a result of the medications used to induce hy-
peremia, most commonly adenosine. Adenosine 
causes above all, transient disturbances in atrio-
ventricular conduction, and rarely, ventricular 
arrhythmias, which occur more commonly when 
given i.c. [16, 17]. Application of the drug is as-
sociated with a benign sensation of discomfort 
in the chest, which quickly dissipates, with no 
negative consequences. A more serious problem 
that occurs is the mechanical damage to the vessel 
wall by the catheter used to measure the FFR and 
pressure wire. Although a rare occurrence, it can 
lead to dissection of the vessel, and, in extreme 
cases, perforation [54]. 
Limitations of FFR assessment in ACS
Acute coronary syndrome in contrast to CAD 
is more frequently associated with various factors 
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that could prevent FFR measurement. As a result, 
these factors are deemed significant contraindica-
tions to performing the procedure; they include 
bradycardia, hypotension, hemodynamic instabil-
ity or severe arrhythmias. Last but not least, the 
FFR-measurement is often not possible when the 
vessel is occluded completely or critically stenosed 
with delayed collateral circulation [49].
Conclusions and future perspectives
Only a few RCT have been performed show-
ing the efficacy of FFR-guided PCI in ACS Thus, 
its role in acute scenarios is clearly understudied.
Although the clinical relevance of FFR-
-measurement in acute course of ACS still remains 
controversial, it appears that use of FFR could 
prove to be an excellent tool to assess the sig-
nificance of non-culprit stenosis especially in 
a setting of NSTEMI and MVD. Consequently, 
the entire plan of the treatment strategy of a pa-
tient could be determined already during the first 
angiographic procedure. Reliable tools to aid in 
the assessment of non-culprit lesions during the 
initial coronary intervention could significantly 
impact treatment strategies in patients with MI. 
An early evaluation of the area of cardiac muscle at 
risk of ischemia could lead to better risk stratifica-
tion and a more adequate qualification of patients 
for further revascularization. On the other hand, 
FFR assessment of non-culprit lesions in the 
acute phase of MI could prove to be inaccurate 
with regards to microvascular dysfunction and the 
challenges of obtaining optimal conditions for this 
examination [30, 55]. Easily, this could lead to an 
underestimation or overestimation of the severity 
of stenosis, which as a consequence, could result 
in choosing a suboptimal type of therapy [55–57]. 
Most recently in the literature, it has been shown 
that revascularization of functionally significant 
non-culprit stenoses within the first month after 
MI is associated with a better long-term outcome. 
In contrast, non-culprit lesions that are not sig-
nificant rarely display signs of progression [34]. 
Taking this into account, it can be easily  predicted 
how important a role FFR measurements could 
play in the assessment of significant non-culprit 
stenoses in ACS, and at the same time, impact 
the approach to patient management. 
There is little doubt, that the assessment 
of FFR in patients with ACS certainly demands 
further RCTs to accurately confirm or deny the 
importance of performing FFR measurements 
during the acute phase of MI. FFR has a chance of 
becoming an essential tool for physicians not only 
in stable CAD, as it is currently used, but also dur-
ing PCI of patients with ACS. This topic requires 
further analysis and more refined trials on a broader 
group of patients, to allow for complete confidence 
in confirming the reliability of FFR measurements 
obtained in patients with ACS.  
The potential clinical utility of a FFR-guided 
management in ACS patients with MVD is still 
being studied in COMPLETE STUDY, FULL 
REVASC and PRAMI-2 trials.
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